These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
106 related items for PubMed ID: 12929575
1. The effects of epirubicin hydrochloride (EPI) plus pretreatment of medroxyprogesterone acetate (MPA) on FM3A breast cancer cells transplanted in female C3H/He mice. Yuyama Y, Yagihashi A, Hirata K, Suzuki Y, Ohmura T, Okazaki M, Watanabe N. In Vivo; 2003; 17(3):251-4. PubMed ID: 12929575 [Abstract] [Full Text] [Related]
2. Inhibition of tumor angiogenesis activity in C3H mouse mammary tumor by medroxyprogesterone acetate. Fujimoto J, Hosoda S, Fujita H, Okada H. Nihon Sanka Fujinka Gakkai Zasshi; 1989 Jan; 41(1):77-82. PubMed ID: 2466926 [Abstract] [Full Text] [Related]
8. Interleukin-12 inhibits angiogenesis and growth of transplanted but not in situ mouse mammary tumor virus-induced mammary carcinomas. Lee JC, Kim DC, Gee MS, Saunders HM, Sehgal CM, Feldman MD, Ross SR, Lee WM. Cancer Res; 2002 Feb 01; 62(3):747-55. PubMed ID: 11830529 [Abstract] [Full Text] [Related]
9. Embryonal mass and hormone-associated effects of pregnancy inducing a differential growth of four murine tumors. Bustuoabad OD, di Gianni PD, Franco M, Kordon EC, Vanzulli SI, Meiss RP, Grion LC, Díaz GS, Nosetto SH, Hockl P, Lombardi MG, Pasqualini CD, Ruggiero RA. Oncol Res; 2002 Feb 01; 13(3):147-60. PubMed ID: 12549624 [Abstract] [Full Text] [Related]
12. A randomized study on hormone-resistant prostatic cancer: estramustine phosphate versus low dose epirubicin with or without medroxyprogesterone acetate. A Norwegian multicenter study. Tveter KJ, Hagen S, Holme I, Klepp O, Kloster SE, Muri O, Poulsen C, Sander S, Sivertsen S, Urnes T. Scand J Urol Nephrol; 1990 Feb 01; 24(4):243-7. PubMed ID: 2148830 [Abstract] [Full Text] [Related]
16. Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors. Coxon A, Bush T, Saffran D, Kaufman S, Belmontes B, Rex K, Hughes P, Caenepeel S, Rottman JB, Tasker A, Patel V, Kendall R, Radinsky R, Polverino A. Clin Cancer Res; 2009 Jan 01; 15(1):110-8. PubMed ID: 19118038 [Abstract] [Full Text] [Related]